ERBB2 and breast cancer: Another phase 2 clinical study involving women with Her2+ BC corroborated these findings, showing that patients administered pertuzumab, trastuzumab, and docetaxel exhibited a significantly enhanced treatment response rate compared to those receiving trastuzumab and docetaxel alone [70].